Fakih 博士談 FDA 批准 Sotorasib 聯合 Panitumumab 用於治療 KRAS G12C 突變型轉移性結直腸癌 – OncLive
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC OncLive
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
文章相關商品
系統已根據文章標題、摘要和正文，自動匹配目前在售的強相關藥品。
索托拉西布錠 SOTOLDX Sotorasib 120mg
2021年5月29日，美國FDA宣布加速核准索拓拉西AMG510（Sotorasib）上市，用於治療腫瘤攜帶KRAS G12C突變的非小細胞肺癌（NSCLC）病患。這些患者至少接受過一種前期全身性治療。這是全球首款針對特定KRAS基因突變的抗癌療法。
查看商品
常見問題
Which products are related to this article?
The system matched these relevant products from the article content: 盧修斯 索托拉西布 Sotorasib 在線購買、索托拉西布錠 SOTOLDX Sotorasib 120mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
